Indeed, a total of nine cohort studies, selected from 535 identified articles and involving 579,256 patients with type 2 diabetes mellitus (T2DM), reported that the use of GLP-1R agonists was associated with a decreased risk of developing hepatocellular carcinoma and experiencing cirrhosis decompensation. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.